The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50

Sponsor
Inova Health Care Services (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05419531
Collaborator
(none)
100
1
36
2.8

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the frequency of colorectal cancer in male and female endurance athletes between the ages of 35 and 50.

Condition or Disease Intervention/Treatment Phase
  • Other: prospective observational study - screening and follow up colonoscopy

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Measuring the Incidence of Colorectal Cancer in Young Endurance Athletes
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Aug 31, 2025
Anticipated Study Completion Date :
Aug 31, 2025

Outcome Measures

Primary Outcome Measures

  1. rate of young endurance athletes that have adenomatous polyps [36 months]

    The rate of adenomatous polyps and colorectal cancer will be estimated with their 95% confidence intervals using the exact binomial method

  2. rate of young endurance athletes that have colorectal cancer on screening colonoscopies. [36 months]

    The rate of adenomatous polyps and colorectal cancer will be estimated with their 95% confidence intervals using the exact binomial method

Secondary Outcome Measures

  1. comparison of the rate of young endurance athletes that have adenomatous polyps with that of the historical controls (those in the average risk group) [36 months]

    Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls.

  2. Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group). [36 months]

    Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls.

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult males and females 35-50 years of age

  • Male and female self-reported endurance athletes, defined by at least one of the following:

  • Run at least two races of 50 miles or more

  • Run 5 races of 26.2 miles or more

  • Ability to complete testing in the protocol and make study visits

  • Able and willing to consent to protocol

Exclusion Criteria:
  • Known or suspected history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or Lynch Syndrome

  • Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.

  • Anticipated poor compliance

  • Prisoners or subjects who are involuntarily incarcerated

  • Persons with decisional incapacity/cognitive impairment

  • Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study

  • Subject is involved with a worker's compensation, personal injury, or other legal matters related to their health

  • Subject is enrolled in a separate interventional clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Inova Schar Cancer Institute Fairfax Virginia United States 22031

Sponsors and Collaborators

  • Inova Health Care Services

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Inova Health Care Services
ClinicalTrials.gov Identifier:
NCT05419531
Other Study ID Numbers:
  • U21-10-4567
First Posted:
Jun 15, 2022
Last Update Posted:
Aug 24, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2022